866-997-4948(US-Canada Toll Free)

Breast Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016

Published By :

GlobalData

Published Date : Dec 2016

Category :

Cancer

No. of Pages : 537 Pages

Breast Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016

Summary

GlobalData's Medical Devices sector report, Breast Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016" provides an overview of Breast Cancer Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Breast Cancer Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Breast Cancer Diagnostic Tests under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Breast Cancer Diagnostic Tests and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Breast Cancer Diagnostic Tests under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the products current stage of development, territory and estimated launch date
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 13
1.2 List of Figures 28
2 Introduction 29
2.1 Breast Cancer Diagnostic Tests Overview 29
3 Products under Development 30
3.1 Breast Cancer Diagnostic Tests - Pipeline Products by Stage of Development 30
3.2 Breast Cancer Diagnostic Tests - Pipeline Products by Territory 31
3.3 Breast Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 32
3.4 Breast Cancer - Pipeline Products by Estimated Approval Date 33
3.5 Breast Cancer Diagnostic Tests - Ongoing Clinical Trials 34
4 Breast Cancer Diagnostic Tests - Pipeline Products under Development by Companies 35
4.1 Breast Cancer Diagnostic Tests Companies - Pipeline Products by Stage of Development 35
4.2 Breast Cancer Diagnostic Tests - Pipeline Products by Stage of Development 42
5 Breast Cancer Diagnostic Tests Companies and Product Overview 50
5.1 A&G Pharmaceutical Inc Company Overview 50
5.2 Abbott Diagnostics Company Overview 52
5.3 Abviva, Inc. Company Overview 58
5.4 Accelerated Medical Diagnostics Company Overview 59
5.5 Acobiom Company Overview 60
5.6 Affichem SA Company Overview 62
5.7 AIT Austrian Institute of Technology GmbH Company Overview 64
5.8 Albert-Ludwigs-Universitat Freiburg Company Overview 65
5.9 Almac Diagnostics Ltd Company Overview 66
5.10 Amarantus Bioscience Holdings Inc Company Overview 67
5.11 AngioGenex Inc Company Overview 69
5.12 Anixa Diagnostics Corporation Company Overview 73
5.13 Armune BioScience, Inc. Company Overview 74
5.14 Arno Therapeutics Inc Company Overview 75
5.15 ArtemixRx Company Overview 77
5.16 Ascendant Diagnostics, LLC Company Overview 78
5.17 Assurance Biosciences, Inc. (Inactive) Company Overview 79
5.18 Atossa Genetics, Inc. Company Overview 80
5.19 Aurelium BioPharma Inc. Company Overview 84
5.20 Autoimmune Technologies LLC Company Overview 86
5.21 Ayanda Biosystems SA (Inactive) Company Overview 87
5.22 Baylor College of Medicine Company Overview 88
5.23 BCAL Diagnostics Pty Limited Company Overview 90
5.24 Becton Dickinson and Company Company Overview 91
5.25 Biocartis SA Company Overview 93
5.26 Biocrates Life Sciences AG Company Overview 94
5.27 Biodesix Inc Company Overview 95
5.28 BioMarCare Technologies Ltd. Company Overview 96
5.29 BioMark Diagnostics Inc. Company Overview 98
5.30 BioMarker Strategies LLC Company Overview 99
5.31 bioMerieux S.A. Company Overview 100
5.32 Biomoda, Inc. (Inactive) Company Overview 101
5.33 Biosceptre (Aust) Pty Ltd Company Overview 102
5.34 BioSystems International Company Overview 103
5.35 Bio-Techne Corp Company Overview 104
5.36 bioTheranostics Inc Company Overview 106
5.37 BioTime Inc Company Overview 107
5.38 Caprion Biosciences Inc Company Overview 109
5.39 Cellanyx Diagnostics, Inc. Company Overview 110
5.40 CellMax Life Company Overview 111
5.41 CellXplore, Inc. Company Overview 112
5.42 Centro de Investigacion y Asistencia en Tecnologia y Diseno del Estado de Jalisco Company Overview 113
5.43 Cepheid Company Overview 114
5.44 Ceres Nanosciences Inc Company Overview 117
5.45 Cernostics Inc. Company Overview 118
5.46 China Sky One Medical Inc Company Overview 119
5.47 Chronix Biomedical Inc Company Overview 120
5.48 Clarient Inc Company Overview 121
5.49 Cleveland Diagnostics Inc. Company Overview 122
5.50 CompanDX Ltd. Company Overview 123
5.51 Courtagen Life Sciences Inc Company Overview 124
5.52 CS-Keys, Inc. Company Overview 125
5.53 Da An Gene Co Ltd Company Overview 126
5.54 Dana-Farber Cancer Institute Inc Company Overview 128
5.55 Dartmouth College Company Overview 129
5.56 Diaxonhit SA Company Overview 130
5.57 Dublin City University Company Overview 133
5.58 Emergence BioScreening, LLC Company Overview 134
5.59 Eventus Diagnostics Inc (Inactive) Company Overview 135
5.60 Exiqon A/S Company Overview 139
5.61 Exosomics Siena SpA Company Overview 140
5.62 Fahy Gurteen UK Ltd Company Overview 141
5.63 Fina Biotech Company Overview 142
5.64 Fluxion Biosciences, Inc. Company Overview 143
5.65 Fournira Optime Diagnostics Company Overview 144
5.66 French National Institute of Health and Medical Research Company Overview 145
5.67 GeneNews Ltd Company Overview 147
5.68 Genentech Inc Company Overview 149
5.69 GenomicTree Inc Company Overview 151
5.70 Genoptix Inc Company Overview 152
5.71 George Washington University Company Overview 154
5.72 German Cancer Research Center Company Overview 155
5.73 Ghent University Company Overview 157
5.74 GlycoZym Company Overview 158
5.75 H. Lee Moffitt Cancer Center & Research Institute Inc Company Overview 159
5.76 Hai Kang Life Corp Ltd Company Overview 160
5.77 Health Discovery Corp Company Overview 161
5.78 Hebrew University of Jerusalem Company Overview 162
5.79 Heragen, Inc. Company Overview 163
5.80 Hummingbird Diagnostics GmbH Company Overview 164
5.81 Ikonisys Inc Company Overview 165
5.82 IncellDx Inc Company Overview 166
5.83 Innovative Health Diagnostics Company Overview 168
5.84 Insight Genetics Inc Company Overview 169
5.85 Institute of Cancer Research Company Overview 171
5.86 Inverness Medical Canada Inc. (Inactive) Company Overview 172
5.87 IRIS International, Inc. Company Overview 173
5.88 ITUS Corporation Company Overview 174
5.89 IV Diagnostics, Inc. Company Overview 175
5.90 John Hopkins University Company Overview 176
5.91 Jonakee Cancer Research, Inc. Company Overview 180
5.92 Kailos Genetics, Inc. Company Overview 181
5.93 Kalgene Pharmaceuticals Inc. Company Overview 182
5.94 Leica Biosystems GmbH Company Overview 183
5.95 Louisville Bioscience, Inc. Company Overview 184
5.96 MabCure Inc. Company Overview 185
5.97 Matrix-Bio, Inc. Company Overview 186
5.98 MDNA Life Sciences Inc Company Overview 189
5.99 MDxHealth SA Company Overview 190
5.100 Medical Prognosis Institute A/S Company Overview 192
5.101 MEDITE Cancer Diagnostics Inc Company Overview 196
5.102 MedMira Inc. Company Overview 198
5.103 Metabolomic Technologies Inc Company Overview 200
5.104 MetaStat Inc Company Overview 201
5.105 Milagen, Inc. Company Overview 203
5.106 MiRXES Pte Ltd Company Overview 204
5.107 Molecular Warehouse Ltd Company Overview 205
5.108 Myriad Genetics Inc Company Overview 206
5.109 NanoString Technologies Inc Company Overview 208
5.110 National University of Ireland, Galway Company Overview 210
5.111 New York University Company Overview 211
5.112 Newcastle University Company Overview 212
5.113 Novel Bio-spectrum Technologies, Inc. Company Overview 214
5.114 Nuclea Biotechnologies Inc. (Inactive) Company Overview 216
5.115 Nuvera Biosciences Inc Company Overview 219
5.116 Olink Proteomics AB Company Overview 223
5.117 Olympia Diagnostics, Inc Company Overview 225
5.118 Onconome, Inc. (Inactive) Company Overview 226
5.119 OncoStem Diagnostics Pvt. Ltd Company Overview 228
5.120 OncoVista Innovative Therapies Inc Company Overview 229
5.121 On-Q-ity, Inc. (Inactive) Company Overview 231
5.122 Orion Genomics LLC Company Overview 232
5.123 OTraces Inc. Company Overview 233
5.124 Oxford Impedance Diagnostics Ltd Company Overview 234
5.125 PeriRx LLC Company Overview 235
5.126 Power3 Medical Products, Inc. Company Overview 236
5.127 Precision Biologics Inc Company Overview 238
5.128 PreMD Inc Company Overview 239
5.129 Princeton University Company Overview 240
5.130 Proplex Technologies Llc Company Overview 241
5.131 Protagen AG Company Overview 242
5.132 Proteome Sciences Plc Company Overview 243
5.133 Proteomika Company Overview 245
5.134 Provista Diagnostics Inc. Company Overview 246
5.135 Qiagen NV Company Overview 247
5.136 Quest Diagnostics Inc Company Overview 249
5.137 Rna Diagnostics Inc. Company Overview 251
5.138 Roche Diagnostics International Ltd Company Overview 253
5.139 Rosetta Genomics Ltd Company Overview 256
5.140 Royal College of Surgeons in Ireland Company Overview 258
5.141 RWTH Aachen University Company Overview 259
5.142 Savicell Diagnostic Ltd. Company Overview 260
5.143 Selventa Inc Company Overview 261
5.144 Sengenics International Pte Ltd Company Overview 262
5.145 Siamab Therapeutics Inc Company Overview 263
5.146 Siemens Healthcare GmbH Company Overview 264
5.147 Soricimed Biopharma Inc Company Overview 265
5.148 Target Discovery, Inc. Company Overview 267
5.149 Taxor Diagnostics, LLC Company Overview 268
5.150 TechnoGenesys, Inc. Company Overview 269
5.151 The University of Texas MD Anderson Cancer Center Company Overview 270
5.152 Todos Medical Company Overview 272
5.153 Trinity College Dublin Company Overview 273
5.154 Universal Diagnostics, S. L. Company Overview 274
5.155 Universite De Lyon Company Overview 275
5.156 University of Alberta Company Overview 276
5.157 University of Bonn Company Overview 277
5.158 University of California Riverside Company Overview 279
5.159 University of California San Diego Company Overview 280
5.160 University of Chicago Company Overview 281
5.161 University of Colorado Company Overview 282
5.162 University of Iowa Company Overview 284
5.163 University of Maryland, Baltimore Company Overview 286
5.164 University of Nebraska Company Overview 287
5.165 University of Oxford Company Overview 288
5.166 University of South Florida Company Overview 289
5.167 University of Wisconsin Madison Company Overview 290
5.168 US Biomarkers Inc Company Overview 291
5.169 Vermillion Inc Company Overview 292
5.170 Viomics Inc. Company Overview 294
5.171 Vitatex Inc. Company Overview 295
5.172 Vitruvian Biomedical, Inc. Company Overview 296
5.173 VolitionRX Ltd Company Overview 297
5.174 XEPTAGEN SpA Company Overview 299
5.175 Xiamen Zeesan Biotech Co.,Ltd Company Overview 301
5.176 Zetiq Technologies Ltd Company Overview 302
6 Breast Cancer Diagnostic Tests - Recent Developments 304
6.1 Nov 21, 2016: Anthony J. Maddaluna, Executive Vice President and President of Pfizer Global Supply to Retire 304
6.2 Nov 17, 2016: AroCell: Interim report, 1 January 30 September 2016 304
6.3 Nov 17, 2016: AroCell: Interim report January - September 2016 305
6.4 Nov 15, 2016: Oncocyte Announces Publication Of Breast Cancer Diagnostic Test Abstract; Poster To Be Presented At The San Antonio Breast Cancer Symposium On December 9, 2016 306
6.5 Nov 15, 2016: Braster to Raise USD2.6 Million in Public Offering of Series A Bonds 307
6.6 Nov 15, 2016: Dilon Diagnostics Enters into Distribution Agreement with GE Healthcare in North America 307
6.7 Nov 15, 2016: One thousand cancer patients have gene testing through efficient, affordable new process 307
6.8 Nov 14, 2016: Atossa Genetics Announces Third Quarter 2016 Financial Results and Provides Company Update 308
6.9 Nov 14, 2016: Vermillion appoints chief medical officer 309
6.10 Nov 14, 2016: HTG Molecular Diagnostics Reports Third Quarter 2016 Results 310
6.11 Nov 14, 2016: Arno Therapeutics Reports Third Quarter 2016 Financial and Business Update 310
6.12 Nov 11, 2016: GeneNews Announces Q3-2016 Financial Results and Provides Corporate Update 311
6.13 Nov 10, 2016: Oncocyte Reports Third Quarter 2016 Financial Results 313
6.14 Nov 10, 2016: Vermillion Reports Third Quarter 2016 Results 314
6.15 Nov 10, 2016: VolitionRx Announces Third Quarter 2016 Financial Results and Business Update 315
6.16 Nov 09, 2016: Biocept Reports 2016 Third Quarter Financial Results 316
6.17 Nov 03, 2016: Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update 318
6.18 Nov 03, 2016: BD Announces Results For 2016 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2017 Guidance 320
6.19 Nov 03, 2016: BioTime Reports Third Quarter Results and Recent Clinical Progress 321
6.20 Nov 03, 2016: Genetic Counselor Mandate Creates a Barrier to BRCA1/2 Testing, New Study Finds 323
6.21 Nov 03, 2016: Ann Hammarstrand Appointed as New CFO to AroCell 324
6.22 Nov 02, 2016: MDxHealth Raises USD22.4 Million in Private Placement of Shares 324
6.23 Nov 02, 2016: MDxHealth Provides Third Quarter 2016 Business Update 325
6.24 Nov 02, 2016: Foundation Medicine Announces 2016 Third Quarter Results and Recent Highlights 326
6.25 Nov 02, 2016: QIAGEN Reports Results for Third Quarter and First Nine Months of 2016 327
6.26 Nov 02, 2016: NanoString Technologies Releases Operating Results for Third Quarter of 2016 330
6.27 Nov 01, 2016: Pfizer Reports Third-Quarter 2016 Results 331
6.28 Nov 01, 2016: Genomic Health Reports Third Consecutive Quarter of Double-Digit Revenue Growth in Announcement of Third Quarter 2016 Financial Results 336
6.29 Oct 31, 2016: Proteome Sciences to Raise USD4 Million in Private Placement of Shares 337
6.30 Oct 27, 2016: Biocept Appoints David Moskowitz Vice President, Strategy & Corporate Communications 337
6.31 Oct 27, 2016: Astellas Reports First Half FY2016 Financial Results, Revises Fiscal Year Outlook 338
6.32 Oct 27, 2016: Foundation Medicine Adds Life Sciences Leader Michael R. Dougherty to its Board of Directors 339
6.33 Oct 26, 2016: NeoGenomics Reports 142% Revenue Growth to $60.8 Million and a Record $9.6 Million in Cash Flow from Operations in the Third Quarter of 2016 340
6.34 Oct 26, 2016: GlaxoSmithKline: Results Announcement for the third quarter 2016 341
6.35 Oct 26, 2016: Ipsen Reports 12.2%1 Sales Growth for the Third Quarter of 2016 and Raises Full Year Guidance 347
6.36 Oct 26, 2016: OncoDNA Signs Agreement with SOLTI to Provide Tumor Molecular Profile Analysis to Breast Cancer Patients in AGATA Screening Program 348
6.37 Oct 25, 2016: Novartis delivered solid third quarter with Growth Products offsetting Gleevec patent expiration; several positive readouts for potential blockbusters 349
6.38 Oct 20, 2016: bioMerieux-Business Review for the nine months ended September 30, 2016 355
6.39 Oct 20, 2016: Quest Diagnostics Reports Third Quarter 2016 Financial Results 357
6.40 Oct 20, 2016: Rosetta Genomics Appoints Mark R. Willig as Chief Commercial Officer 359
6.41 Oct 14, 2016: Biocept Raises USD10 Million in Public Offering of Shares and Warrants 360
6.42 Oct 13, 2016: Provista Diagnostics Raises USD2.6 Million in Venture Financing 360
6.43 Oct 07, 2016: Myriad Announces Poster Presentation on Tumor BRACAnalysis CDx test at the 2016 European Society for Medical Oncology (ESMO) Annual Meeting 360
6.44 Oct 07, 2016: Myriad Announces Poster Presentations on myChoice HRD test at the 2016 European Society for Medical Oncology (ESMO) Annual Meeting 361
6.45 Oct 05, 2016: OncoTAb Enters into Agreement with National Cancer Institute 362
6.46 Oct 03, 2016: UE LifeSciences Raises USD1.2 Million in Venture Financing 362
7 Appendix 530
7.1 Methodology 530
7.2 About GlobalData 533
7.3 Contact Us 533
7.4 Disclaimer 533

1.1 List of Tables
Table 1: Breast Cancer Diagnostic Tests - Pipeline Products by Stage of Development 34
Table 2: Breast Cancer Diagnostic Tests - Pipeline Products by Territory 35
Table 3: Breast Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 36
Table 4: Breast Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 37
Table 5: Breast Cancer Diagnostic Tests - Ongoing Clinical Trials 38
Table 6: Breast Cancer Diagnostic Tests Companies - Pipeline Products by Stage of Development 39
Table 7: Breast Cancer Diagnostic Tests - Pipeline Products by Stage of Development 46
Table 8: A&G Pharmaceutical Inc Pipeline Products & Ongoing Clinical Trials Overview 54
Table 9: Onco 88 - Breast Cancer - Product Status 54
Table 10: Onco 88 - Breast Cancer - Product Description 55
Table 11: OncoStain 88 - Breast Cancer - Product Status 55
Table 12: OncoStain 88 - Breast Cancer - Product Description 55
Table 13: Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 56
Table 14: AKT Companion Diagnostic Assay - Breast Cancer - Product Status 56
Table 15: AKT Companion Diagnostic Assay - Breast Cancer - Product Description 57
Table 16: CKS1B Companion Diagnostic Assay - Breast Cancer - Product Status 57
Table 17: CKS1B Companion Diagnostic Assay - Breast Cancer - Product Description 57
Table 18: cMET Companion Diagnostic Assay - Breast Cancer - Product Status 58
Table 19: cMET Companion Diagnostic Assay - Breast Cancer - Product Description 58
Table 20: PIK3CA Companion Diagnostic Assay - Breast Cancer - Product Status 58
Table 21: PIK3CA Companion Diagnostic Assay - Breast Cancer - Product Description 59
Table 22: PTEN Companion Diagnostic Assay - Breast Cancer - Product Status 59
Table 23: PTEN Companion Diagnostic Assay - Breast Cancer - Product Description 59
Table 24: TOP2A Companion Diagnostic Assay - Breast Cancer - Product Status 60
Table 25: TOP2A Companion Diagnostic Assay - Breast Cancer - Product Description 60
Table 26: ZNF217 Companion Diagnostic Assay - Breast Cancer - Product Status 60
Table 27: ZNF217 Companion Diagnostic Assay - Breast Cancer - Product Description 61
Table 28: Abviva, Inc. Pipeline Products & Ongoing Clinical Trials Overview 62
Table 29: Diagnostic Assay - Mammastatin - Product Status 62
Table 30: Diagnostic Assay - Mammastatin - Product Description 62
Table 31: Accelerated Medical Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 63
Table 32: Companion Diagnostic Test - Oxaliplatin - Product Status 63
Table 33: Companion Diagnostic Test - Oxaliplatin - Product Description 63
Table 34: Acobiom Pipeline Products & Ongoing Clinical Trials Overview 64
Table 35: Companion Diagnostic Test - Breast Cancer - Product Status 64
Table 36: Companion Diagnostic Test - Breast Cancer - Product Description 64
Table 37: Companion Diagnostic Test - Triple Negative Breast Cancer - Product Status 65
Table 38: Companion Diagnostic Test - Triple Negative Breast Cancer - Product Description 65
Table 39: Affichem SA Pipeline Products & Ongoing Clinical Trials Overview 66
Table 40: AF300 Based Chromatographic Kit - Product Status 66
Table 41: AF300 Based Chromatographic Kit - Product Description 66
Table 42: AF300 Based Enzymatic Immunoassay Kit - Product Status 67
Table 43: AF300 Based Enzymatic Immunoassay Kit - Product Description 67
Table 44: AIT Austrian Institute of Technology GmbH Pipeline Products & Ongoing Clinical Trials Overview 68
Table 45: Diagnostic Assay - Breast Cancer - Product Status 68
Table 46: Diagnostic Assay - Breast Cancer - Product Description 68
Table 47: Albert-Ludwigs-Universitat Freiburg Pipeline Products & Ongoing Clinical Trials Overview 69
Table 48: mRNA Based Diagnostic Assay - Breast Cancer - Product Status 69
Table 49: mRNA Based Diagnostic Assay - Breast Cancer - Product Description 69
Table 50: Almac Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview 70
Table 51: Diagnostic Test - Breast Cancer - Product Status 70
Table 52: Diagnostic Test - Breast Cancer - Product Description 70
Table 53: Amarantus Bioscience Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview 71
Table 54: NuroPro - Breast Cancer - Product Status 71
Table 55: NuroPro - Breast Cancer - Product Description 72
Table 56: AngioGenex Inc Pipeline Products & Ongoing Clinical Trials Overview 73
Table 57: Diagnostic/Prognostic/Surrogate Marker Test - Breast Cancer - Product Status 73
Table 58: Diagnostic/Prognostic/Surrogate Marker Test - Breast Cancer - Product Description 74
Table 59: Id1 Surrogate Marker Diagnostic Or Prognostic Test - Product Status 74
Table 60: Id1 Surrogate Marker Diagnostic Or Prognostic Test - Product Description 74
Table 61: Id2 Surrogate Marker Diagnostic Or Prognostic Test - Product Status 75
Table 62: Id2 Surrogate Marker Diagnostic Or Prognostic Test - Product Description 75
Table 63: Id3 Surrogate Marker Diagnostic or Prognostic Test - Product Status 75
Table 64: Id3 Surrogate Marker Diagnostic or Prognostic Test - Product Description 76
Table 65: Id4 Surrogate Marker Diagnostic Or Prognostic Test - Product Status 76
Table 66: Id4 Surrogate Marker Diagnostic Or Prognostic Test - Product Description 76
Table 67: Anixa Diagnostics Corporation Pipeline Products & Ongoing Clinical Trials Overview 77
Table 68: Biomarker Test - Breast Cancer - Product Status 77
Table 69: Biomarker Test - Breast Cancer - Product Description 77
Table 70: Armune BioScience, Inc. Pipeline Products & Ongoing Clinical Trials Overview 78
Table 71: Diagnostic Test - Breast Cancer - Product Status 78
Table 72: Diagnostic Test - Breast Cancer - Product Description 78
Table 73: Arno Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 79
Table 74: Activated Estrogen Receptor Biomarker Assay - Product Status 79
Table 75: Activated Estrogen Receptor Biomarker Assay - Product Description 80
Table 76: Onapristone Companion Diagnostic Assay - Breast Cancer - Product Status 80
Table 77: Onapristone Companion Diagnostic Assay - Breast Cancer - Product Description 80
Table 78: ArtemixRx Pipeline Products & Ongoing Clinical Trials Overview 81
Table 79: ArtemixRx Prognostic Test - Breast Cancer - Product Status 81
Table 80: ArtemixRx Prognostic Test - Breast Cancer - Product Description 81
Table 81: Ascendant Diagnostics, LLC Pipeline Products & Ongoing Clinical Trials Overview 82
Table 82: MelodyDX - Product Status 82
Table 83: MelodyDX - Product Description 82
Table 84: Assurance Biosciences, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 83
Table 85: Salivary-Based Assay - Breast Cancer - Product Status 83
Table 86: Salivary-Based Assay - Breast Cancer - Product Description 83
Table 87: Atossa Genetics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 84
Table 88: ArgusCYTE Breast Health Test - Product Status 84
Table 89: ArgusCYTE Breast Health Test - Product Description 85
Table 90: Companion Diagnostic Test - Breast Cancer - Product Status 85
Table 91: Companion Diagnostic Test - Breast Cancer - Product Description 85
Table 92: Next Generation MASCT System - Product Status 86
Table 93: Next Generation MASCT System - Product Description 86
Table 94: NextCYTE Breast Cancer Test - Product Status 86
Table 95: NextCYTE Breast Cancer Test - Product Description 87
Table 96: Aurelium BioPharma Inc. Pipeline Products & Ongoing Clinical Trials Overview 88
Table 97: Breast Cancer Screening Test - Product Status 88
Table 98: Breast Cancer Screening Test - Product Description 88
Table 99: MMD ELISA Test - Breast Cancer - Product Status 89
Table 100: MMD ELISA Test - Breast Cancer - Product Description 89
Table 101: Autoimmune Technologies LLC Pipeline Products & Ongoing Clinical Trials Overview 90
Table 102: Diagnostic Assay - Breast Cancer - Product Status 90
Table 103: Diagnostic Assay - Breast Cancer - Product Description 90
Table 104: Ayanda Biosystems SA (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 91
Table 105: Diagnostic Test - Breast Cancer - Product Status 91
Table 106: Diagnostic Test - Breast Cancer - Product Description 91
Table 107: Baylor College of Medicine Pipeline Products & Ongoing Clinical Trials Overview 92
Table 108: Mitochondria-Regulated Cancer Signature - Breast Cancer - Product Status 92
Table 109: Mitochondria-Regulated Cancer Signature - Breast Cancer - Product Description 93
Table 110: BCAL Diagnostics Pty Limited Pipeline Products & Ongoing Clinical Trials Overview 94
Table 111: BCAL Test - Breast Cancer - Product Status 94
Table 112: BCAL Test - Breast Cancer - Product Description 94
Table 113: Becton Dickinson and Company Pipeline Products & Ongoing Clinical Trials Overview 95
Table 114: Diagnostic Test - Breast Cancer - Product Status 95
Table 115: Diagnostic Test - Breast Cancer - Product Description 96
Table 116: Biocartis SA Pipeline Products & Ongoing Clinical Trials Overview 97
Table 117: Idylla Liquid Biopsy Test - Breast Cancer - Product Status 97
Table 118: Idylla Liquid Biopsy Test - Breast Cancer - Product Description 97
Table 119: Biocrates Life Sciences AG Pipeline Products & Ongoing Clinical Trials Overview 98
Table 120: Metabolomic Biomarker Assay - Breast Cancer - Product Status 98
Table 121: Metabolomic Biomarker Assay - Breast Cancer - Product Description 98
Table 122: Biodesix Inc Pipeline Products & Ongoing Clinical Trials Overview 99
Table 123: VeriStrat - Breast Cancer - Product Status 99
Table 124: VeriStrat - Breast Cancer - Product Description 99
Table 125: BioMarCare Technologies Ltd. Pipeline Products & Ongoing Clinical Trials Overview 100

1.2 List of Figures
Figure 1: Breast Cancer Diagnostic Tests - Pipeline Products by Stage of Development 34
Figure 2: Breast Cancer Diagnostic Tests - Pipeline Products by Territory 35
Figure 3: Breast Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 36
Figure 4: Breast Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 37
Figure 5: Breast Cancer Diagnostic Tests - Ongoing Clinical Trials 38

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *